ID   A375-16R6-4
AC   CVCL_R755
SY   16R6-4
DR   cancercelllines; CVCL_R755
DR   Cosmic; 1890493
DR   Wikidata; Q54606771
RX   Patent=US9402846;
RX   PubMed=22389471;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI_75045; Dabrafenib (Tafinlar; GSK2118436).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu61Ter (c.181G>T) (p.Gly75Val, c.224G>T); ClinVar=VCV000376309; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Glu69Ter (c.205G>T) (p.Gly83Val, c.248G>T); ClinVar=VCV000376308; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; HGNC:11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
CC   Derived from site: In situ; Leg, skin; UBERON=UBERON_0001511.
DI   NCIt; C3802; Amelanotic melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_R745 ! A375PF11
SX   Female
AG   54Y
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 19-12-24; Version: 19
//
RX   Patent=US9402846;
RA   Dumble M., Gilmer T.M., Kumar R., Laquerre S.G., Lebowitz P.F.,
RA   Morris S.R.;
RT   "Combination of inhibitor of B-Raf and an inhibitor of Akt in the
RT   treatment of cancer.";
RL   Patent number US9402846, 02-Aug-2016.
//
RX   PubMed=22389471; DOI=10.1158/1535-7163.MCT-11-0989;
RA   Greger J.G., Eastman S.D., Zhang V., Bleam M.R., Hughes A.M.,
RA   Smitheman K.N., Dickerson S.H., Laquerre S.G., Liu L., Gilmer T.M.;
RT   "Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired
RT   resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by
RT   NRAS or MEK mutations.";
RL   Mol. Cancer Ther. 11:909-920(2012).
//